Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 5/20 | 0.58 |
| ▸ | CCNE1 | P24864 | 4/20 | 0.58 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.52 |
| ▸ | CDK1 | P06493 | 1/20 | 0.51 |
| ▸ | MARK3 | P27448 | 4/20 | 0.47 |
| ▸ | MARK4 | Q96L34 | 2/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | PLK1 | P53350 | 5/20 | 0.45 |
| ▸ | PLK3 | Q9H4B4 | 5/20 | 0.45 |
| ▸ | PLK2 | Q9NYY3 | 5/20 | 0.45 |
| ▸ | SYK | P43405 | 2/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.44 |
| ▸ | PRKDC | P78527 | 1/20 | 0.44 |
| ▸ | RPS6KA6 | Q9UK32 | 2/20 | 0.44 |
| ▸ | STK3 | Q13188 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3971292 | 0.85 | MARK3 (0.49) | CDK2CCNE1CDK1MARK3MARK4 | |
| SCHEMBL3970756 | 0.85 | KDR (0.50) | CDK2CCNE1MARK3MARK4KDR | |
| SCHEMBL25046176 | 0.83 | CDK2 (0.54) | CDK2CCNE1CCNE2CDK1MARK3 | |
| SCHEMBL3971047 | 0.82 | RPS6KA6 (0.64) | CDK2CCNE1CCNE2CDK1MARK3 | |
| SCHEMBL3972914 | 0.82 | CDK2 (0.47) | CDK2CCNE1CCNE2CDK1MARK3 | |
| SCHEMBL3972872 | 0.82 | CDK4 (0.56) | CDK2CCNE1CCNE2CDK1KDR | |
| SCHEMBL3977665 | 0.81 | CDK4 (0.57) | CDK2CCNE1CCNE2CDK1MARK3 | |
| SCHEMBL3970456 | 0.80 | RPS6KA6 (0.49) | CDK2CCNE1MARK3MARK4PLK1 | |
| SCHEMBL3971271 | 0.80 | RPS6KA6 (0.63) | CDK2CCNE1CCNE2CDK1RPS6KA6 | |
| SCHEMBL22165226 | 0.80 | CDK2 (0.61) | CDK2CCNE1CCNE2CDK1MARK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7501425-B1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyprimidines as inhibitors of cellular proliferation | WARNER LAMBERT COMPANY (US) | 2009-03-10 | — | — | US | claimed |
| EP-1801112-A1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation | Warner-Lambert Company LLC (US) | 2007-06-27 | — | — | EP | claimed |
| US-7501425-B1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyprimidines as inhibitors of cellular proliferation | WARNER LAMBERT COMPANY (US) | 2009-03-10 | — | — | US | disclosed |
| EP-1801112-A1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation | Warner-Lambert Company LLC (US) | 2007-06-27 | — | — | EP | disclosed |
| US-20040044012-A1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation | DOBRUSIN ELLEN MYRA (US) | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044012-A1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation | CCNI, CCNH, CCNA1 | CDK2 6/4885CCNE1 12/4885CCNE2 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.